Friday, January 04, 2019 6:43:48 PM
FREEHOLD, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies, announced today that the Company and its wholly owned subsidiary, Avactis Biosciences, have entered into a joint venture and exclusive license agreement with Arbele Limited to co-develop next generation, transposon-based Chimeric Antigen Receptor (CAR)-T and CAR-Natural Killer (NK) cellular therapies. These unique CAR vector constructs are non-virally engineered, possessing multiple therapeutic targets as well as unique “safety-switch" mechanisms. Based on Avalon’s extensive hospital network for cellular therapy, together with the Company’s established GMP bio-production facility in China (Epicon Biotech, Nanjing), this joint venture allows Avalon to accelerate the clinical development of more efficacious and safer CAR-T/CAR-NK therapies, such as those developed by Arbele.
“We are very excited to establish this joint venture with Arbele Limited to accelerate our clinical programs in cellular therapy,” stated David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp. “Arbele’s strong proprietary technology platform in designing and production of non-viral, transposon-engineered, multi-targeted CAR will allow us to generate next-generation, better and safer CAR-T and CAR-NK cellular therapeutics. This joint venture will strengthen our core technological capabilities, enrich our intellectual properties, as well as further establish our leadership in the field of cellular immunotherapy,” added Dr. Jin.
About Arbele Limited
Arbele Limited, founded by industry veterans from Roche, Johnson & Johnson and ICOS Corporation, is a biopharmaceutical company focusing on acceleration and expansion of immunotherapy technology and product development to treat advanced stages of cancers, including those most prevalent in the USA, Australia and the Asia-Pacific region. Arbele Limited has headquarters located in the Hong Kong Science and Technology Park, with its state-of-the-art research hub, Arbele Corp., located in Seattle, WA. Arbele Limited currently holds multiple promising “first-in-class” immuno-oncology candidates (including monoclonal and bi-specific antibodies) within its pipeline. Notably, Arbele’s unique non-viral, transposon-based T cell engineering technology is an exceptional system for rapid delivery of CAR-T cell therapeutics. Later in 2019, phase I clinical studies will be conducted in Australia for refractory or advanced gastrointestinal cancers (including colon, stomach and pancreatic), as well as via joint venture with Avalon GloboCare Corp. for clinical development of CAR-T cellular therapy in China.
Link-here
Recent ALBT News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:31:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 09:01:50 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 08/15/2024 08:05:29 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2024 09:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:29:00 PM
- Avalon’s Laboratory Services MSO to Launch Sales of Proprietary FDA-Registered External Male Catheter Device • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 12:18:14 PM
- Avalon’s Laboratory Services MSO Launches DNA Testing Kit for Predisposition to Opioid Addiction • GlobeNewswire Inc. • 07/31/2024 12:00:00 PM
- Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us • GlobeNewswire Inc. • 07/18/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/18/2024 12:37:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/16/2024 08:05:13 PM
- Avalon GloboCare Provides Update on the Launch of the KetoAir Breathalyzer at Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:54:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 09:10:10 PM
- Avalon GloboCare Receives Notice from Nasdaq Regarding Delayed Quarterly Report • GlobeNewswire Inc. • 05/24/2024 09:00:00 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2024 12:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:30:17 PM
- Avalon GloboCare Announces Launch of U.S. Sales of KetoAir Breathalyzer at the Hack Your Health by KetoCon 2024 Conference • GlobeNewswire Inc. • 04/22/2024 01:00:00 PM
- Avalon GloboCare Extends Exclusivity Agreement to Distribute KetoAir Breathalyzer Device and AI-Enabled Software in North America, South America, United Kingdom and European Union • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- Avalon GloboCare Engages ChtrBx, a Marketing and Branding Company, to Launch KetoAir in the US • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:49:04 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:30:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:30:46 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 10/20/2023 08:18:23 PM
- Avalon GloboCare Partners with Qi Diagnostics to Co-Develop International Multi-Center Clinical Studies for DKAir Breathalyzer Device for the Early Detection of Diabetic Ketoacidosis • GlobeNewswire Inc. • 10/18/2023 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM